Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis

Pediatric Pulmonology

Volumn 49, Issue 11, 2014, Pages 1076-1089

  Mazurek, Henryk ^a   Chiron, Raphaël ^b   Kucerova, Tereza ^c   Geidel, Christian ^d   Bolbas, Katalin ^e   Chuchalin, Alexander ^f   Blanco Aparicio, Marina ^g   Santoro, Debora ^h   Varoli, Guido ^h   Zibellini, Marco ^h   Cicirello, Helen G ^h   Antipkin, Yuriy G ⁱ  

^a INSTYTUT GRU LICY I CHORÓB P UC   (Poland)

^b HÔPITAL ARNAUD DE VILLENEUVE   (France)

^c UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^d JUSTUS LIEBIG UNIVERSITY   (Germany)

^e Gyermekpulmonológiai Részleg   (Hungary)

^f Federal State Institution Scientific Research Pulmonology Institute under the Roszdrav Laboratory of Cystic Fibrosis   (Russian Federation)

^g UNIVERSITY OF A CORUÑA   (Spain)

^h CHIESI FARMACEUTICI S P A   (Italy)

ⁱ Chiesi Pharmaceuticals Inc ^*  (Ukraine)

Author keywords

cystic fibrosis; FEV1; long term; nebulization; Pseudomonas aeruginosa; tobramycin susceptibility

Indexed keywords

TOBRAMYCIN; AEROSOL; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AEROSOL; ANTIBIOTIC SENSITIVITY; ARTICLE; AUDIOMETRY; BRONCHITIS; BRONCHOSPASM; CHILD; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; FORCED EXPIRATORY VOLUME; HEARING DISORDER; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE CYCLE TREATMENT; NEBULIZATION; PHARYNGITIS; PNEUMONIA; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCHOOL CHILD; TREATMENT DURATION; COMPLICATION; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; PATHOPHYSIOLOGY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SPUTUM; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADOLESCENT; AEROSOLS; ANTI-BACTERIAL AGENTS; CHILD; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SPUTUM; TOBRAMYCIN; TREATMENT OUTCOME;

EID: 84892693489     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.22989     Document Type: Article

References (36)

1. Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996; 335:179–188.
2. Gibson RL, Burns, JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crti Care Med 2003; 168:918–951.
3. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ, Willey-Courand DB, Bujan J, Finder J, Lester M, Quittell L, et al. Cystic fibrosis pulmonary guidelines; chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176:957–969.
4. Kerem E, Reisman J, Corey M, Canny G, Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992 326:1187–1191.
5. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry Annual Data Report, 2011. Cystic Fibrosis Foundation, Patient Registry 2011.
6. Banerjee D, Stableforth D. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way? Drugs 2000; 60:1053–1064.
7. Touw DJ, Brimicombe RW, Hodson ME, Heijerman HGM, Bakker W. Inhalation of antibiotics in cystic fibrosis. Eur Respir J 1995; 8:1594–1604.
8. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999; 340:23–30.
9. Toso C, Williams DM, Noone PG. Inhaled antibiotics in cystic fibrosis: a review. Ann Pharmacother 1996; 30:840–850.
10. Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002 121:55–63.
11. Bowman CM. The long-term use of inhaled tobramycin in patients with cystic fibrosis. J Cyst Fibrosis 2002; 1:S194–S198.
12. Poli G, Acerbi D, Pennini R, Sliano Raschini A, Corrado ME, Eichler HG, Eichler I., Clinical pharmacology study of Bramitob®, a tobramycin solution for nebulization, in comparison to Tobi®. Pediatr Drugs 2007; 9:3–9.
13. Lenoir G, Antypkin YG, Miano A, Moretti P, Zanda M, Varoli G, Monici Preti PA, Aryayev NL. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Drugs 2007; 9:11–20.
14. Chuchalin A, Csiszér E, Gyurkovics K, Bartnicka MT, Sands D, Kapranov N, Varoli G, Monici Preti PA, Mazurek H. A formulation of aerosolized tobramycin (Bramitob®) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. Pediatr Drugs 2007; 9:21–31.
15. Fowermaker JE, Laughton CR, Brown DFJ, Bilton D. Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J Antimicrob Chemother 2005; 55:921–927.
16. Morosini ML, Garcia-Castíllo M, Loza E, Peréz-Vázquez M, Baquero F, Cantón R. Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips. J Clin Microbiol 2005; 43:4480–4485.
17. Quanjer P, Tammeling G, Cotes J, Pedersen O, Peslin R, Yernault J. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, european community for steel and coal. Official statement of the European Respiratory Society. Eur Respir J 1993; 6:5–40.
18. Burrows G, Cline MG, Knudson RJ, Taussig LM. A descriptive analysis of the growth and decline of the FVC and FEV1. Chest 1983; 83:717–724.
19. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard-Eighth Edition. CLSI document M07-A8 [ISBN 1-56238-689-1]. Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2009.
20. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Nineteenth Informational Supplement. CLSI document M100-S20 [ISBN 1-56238-716-2]. Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2010.
21. Assael BM, Pressler T, Bilton D, Fayon M, Fischer R, Chiron R, LaRosa M, Knoop C, McElvaney N, Lewis SA, et al. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J Cyst Fibros 2013; 12:130–140.
22. Retsch-Bogart G, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis. Chest 2009; 135:1223–1232.
23. Hodson ME, Gallagher CG, Govan GRW. A randomized clinical trial of nebulized tobramycin or colistin in cystic fibrosis. Eur Resp J 2002; 20:658–664.
24. Ref. EMEAEuropean Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Guideline on the choice of the non-inferiority margin. 27 July 2005. Doc. /CPMP/EWP/2158/99.
25. Chua HL, Collis GG, Le Souef PN. Bronchial response to nebulized antibiotics in children with cystic fibrosis. Eur Respir J 1990; 3:1114–1116.
26. Wood GC, Boucher BA. Aerosolized antimicrobial therapy in acutely ill patients. Pharmacotherapy 2000; 20:166–81.
27. Malvotti C, Garzia R, inventors' Chiesi Farmaceutici SpA, assignee. Optimised formulation of tobramycin for aerosolization. European Patent 1 273 292 B1. May 26, 2004.
28. Fluids and their influences on the body. In: Helba S, Bellegarde M, editors. Handbook of fluid, electrolyte, and acid–base imbalances. Clifton Park, New York: Cengage Learning; 2010. p 8.
29. Tobramycin Inhalation Solution. United States Pharmacopeia-National Formulary Revision Bulletin. April 1, 2013. Rockville, Maryland; 2013.Available from: http://www.usp.org/usp-nf/official-text/revision-bulletins/tobramycin-inhalation-solution.
30. Mathee K, Ciofu O, Sternberg C, Lindum PW, Campbell JIA, Jensen P, Johnsen A, Givskov M, Ohman D, Molin S, Høiby N, Kharazmi A. Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology 1999; 145:1349–1357.
31. Häuβler S, Ziegler I, Löttel A, Götz FV, Rohde M. Wehmhöhner Saravanamuthu S, Tümmler B, Steinmetz I. Highly adherent small-colony variants of Pseudomonas aeruginosa in cystic fibrosis lung infection. J Med Microbiol 2003; 52:295–301.
32. Morlin GL, Hedges DL, Smith AL, Burns JL. Accuracy and cost of antibiotic susceptibility testing of mixed morphotypes of Pseudomonas aeruginosa. J Clin Microbiol 1994; 32:1027–1030.
33. Ciofu O, Fussing V, Bagge N, Koch C, Høiby N. Characterization of paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, β-lactamase activity and RiboPrinting. J Antimicrob Chemother 2001; 48:391–396.
34. LiPuma JJ. Microbiological and immunologic considerations with aerosolized drug delivery. Chest 2001; 120:118S–123S.
35. Schülin T. In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany. J Antimicrob Chemother 2002; 49:403–406.
36. Burns JL, Van Dalfsen JM, Shawar RM, Otto KL, Garber RL, Quan JM, Montgomery AB, Albers GM, Ramsey BW, Smith AL. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999; 179:1190–1196.